NCT01192919已完成不适用
Clinical Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- iOMEDICO AG
- 入组人数
- 2,500
- 主要终点
- Documentation of actually used therapy forms in bronchial carcinoma requiring treatment
研究概览
简要总结
Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.
详细描述
The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
- •written informed consent
- •start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent
排除标准
- •patients not receiving any systemic therapy
结局指标
主要结局
Documentation of actually used therapy forms in bronchial carcinoma requiring treatment
时间窗: 3 years per patient
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Tumor Registry Pancreatic CancerPancreas CancerNCT02089269iOMEDICO AG2,325
已完成
不适用
Tumor Registry of Advanced Renal Cell CarcinomaRenal Cell CarcinomaNCT00610012iOMEDICO AG1,500
已完成
不适用
Tumour Registry Breast CancerBreast CancerNCT01351584iOMEDICO AG4,500
已完成
不适用
Tumor Registry of Lymphatic NeoplasiaNon-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia (CLL)Multiple Myeloma (MM)NCT00889798iOMEDICO AG3,795
已完成
不适用
Bronchial Thermoplasty Global RegistryAsthmaNCT02104856Boston Scientific Corporation158